Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-070921
Filing Date
2025-05-14
Accepted
2025-05-14 07:36:11
Documents
71
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q inzy-20250331.htm   iXBRL 10-Q 1532188
2 EX-31.1 inzy-ex31_1.htm EX-31.1 17803
3 EX-31.2 inzy-ex31_2.htm EX-31.2 17972
4 EX-32.1 inzy-ex32_1.htm EX-32.1 10048
5 EX-32.2 inzy-ex32_2.htm EX-32.2 10101
6 GRAPHIC img189237419_0.jpg GRAPHIC 101095
7 GRAPHIC img189237419_1.jpg GRAPHIC 73436
8 GRAPHIC img189237419_2.jpg GRAPHIC 1735
9 GRAPHIC img189237419_3.jpg GRAPHIC 66024
10 GRAPHIC img189237419_4.jpg GRAPHIC 49285
11 GRAPHIC img189237419_5.jpg GRAPHIC 85532
12 GRAPHIC img189237419_6.jpg GRAPHIC 319937
13 GRAPHIC img189237419_7.jpg GRAPHIC 322987
  Complete submission text file 0000950170-25-070921.txt   9163619

Data Files

Seq Description Document Type Size
14 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inzy-20250331.xsd EX-101.SCH 923118
74 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20250331_htm.xml XML 967247
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

EIN.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39397 | Film No.: 25942668
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)